197 results on '"Fatal anaphylaxis"'
Search Results
2. Fatal food anaphylaxis in adults and children.
- Author
-
Novembre, Elio, Gelsomino, Mariannita, Liotti, Lucia, Barni, Simona, Mori, Francesca, Giovannini, Mattia, Mastrorilli, Carla, Pecoraro, Luca, Saretta, Francesca, Castagnoli, Riccardo, Arasi, Stefania, Caminiti, Lucia, Klain, Angela, and del Giudice, Michele Miraglia
- Subjects
- *
ASTHMA risk factors , *PEANUTS , *RISK assessment , *FOOD allergy , *MILK , *ADRENALINE , *DRUG abuse , *ANAPHYLAXIS , *NUTS , *DISEASE risk factors , *DISEASE complications , *CHILDREN , *ADULTS - Abstract
Anaphylaxis is a life-threatening reaction characterized by the acute onset of symptoms involving different organ systems and requiring immediate medical intervention. The incidence of fatal food anaphylaxis is 0.03 to 0.3 million/people/year. Most fatal food-induced anaphylaxis occurs in the second and third decades of life. The identified risk factors include the delayed use of epinephrine, the presence of asthma, the use of recreational drugs (alcohol, nicotine, cannabis, etc.), and an upright position. In the United Kingdom (UK) and Canada, the reported leading causal foods are peanuts and tree nuts. In Italy, milk seems to be the most common cause of fatal anaphylaxis in children < 18 years. Fatal food anaphylaxis in Italian children and adolescents almost always occurs outside and is characterized by cardiorespiratory arrest; auto-injectable adrenaline intramuscular was available in few cases. Mortality from food anaphylaxis, especially in children, is a very rare event with stable incidence, but its risk deeply impacts the quality of life of patients with food allergy and their families. Prevention of fatal food anaphylaxis must involve patients and their families, as well as the general public, public authorities, and patients' associations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered
- Author
-
Francesca Nicolardi, Federica Corona, Laura Badina, Irene Berti, and Egidio Barbi
- Subjects
Fatal anaphylaxis ,Oral immunotherapy ,Failed immunotherapy ,Omalizumab ,Pediatrics ,RJ1-570 - Abstract
Abstract Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy.
- Published
- 2024
- Full Text
- View/download PDF
4. Response to: ‘Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered’
- Author
-
Elio Novembre, Mariannita Gelsomino, Lucia Liotti, Simona Barni, Francesca Mori, Mattia Giovannini, Carla Mastrorilli, Luca Pecoraro, Francesca Saretta, Riccardo Castagnoli, Stefania Arasi, Lucia Caminiti, Angela Klain, and Michele Miraglia del Giudice
- Subjects
Fatal anaphylaxis ,Food allergy ,Oral immunotherapy ,Epinephrine ,Pediatrics ,RJ1-570 - Published
- 2024
- Full Text
- View/download PDF
5. Analysis of drug-induced anaphylaxis cases using the Japanese Adverse Drug Event Report (JADER) database – secondary publication
- Author
-
Chizuko Sugizaki, Sakura Sato, Noriyuki Yanagida, and Motohiro Ebisawa
- Subjects
Adverse reaction ,Anaphylaxis ,Drug hypersensitivity ,Epidemiology ,Fatal anaphylaxis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: The epidemiology of drug-induced anaphylaxis using the Japanese nationwide database has been not reported, even though drugs are a common trigger of anaphylaxis. The aim of this study was to describe the epidemiological profile of cases of drug-induced anaphylaxis, including fatal cases, using the data from the Japanese Adverse Drug Event Report database (JADER). Methods: We extracted data regarding drug-related adverse events, between April 2004 and February 2018, published in JADER by the Pharmaceuticals and Medical Devices Agency. We analyzed cases of anaphylaxis occurring between January 2005 and December 2017. The drug classification was based on the Japanese Standard Commodity Classification. Results: There were 16,916 cases of anaphylaxis reported during the study period. Among them, 418 fatalities were registered. The incidence of drug-induced anaphylaxis and fatal cases was 1.03 cases/year per 100,000 population and 0.03 cases/year, respectively. The most frequent causes of anaphylaxis were diagnostic agents, including X-ray contrast media (20.3%), and biological preparations, such as human blood preparations (20.1%). In fatal cases, diagnostic agents (28.7%) and antibiotic preparations (23.9%) were the most commonly associated types of drugs. Conclusions: The frequency of drug-induced anaphylaxis and fatalities in Japan remained unchanged over the 13-year period analyzed in this study. Diagnostic agents and biological preparations were the most frequent causes of anaphylaxis; however, fatalities were most frequently caused by either diagnostic agents or antibiotic preparations.
- Published
- 2023
- Full Text
- View/download PDF
6. Fatal Hymenoptera Venom–Triggered Anaphylaxis in Patients with Unrecognized Clonal Mast Cell Disorder—Is Mastocytosis to Blame?
- Author
-
Rijavec, Matija, Inkret, Jezerka, Bidovec-Stojković, Urška, Carli, Tanja, Frelih, Nina, Kukec, Andreja, Korošec, Peter, and Košnik, Mitja
- Subjects
- *
MAST cells , *ANAPHYLAXIS , *MAST cell disease , *EPINEPHRINE autoinjectors , *HYMENOPTERA , *ADRENALINE - Abstract
Hymenoptera venom–triggered anaphylaxis (HVA) affects up to 8.9% of the general population and is the most frequent cause of anaphylaxis in adults, accounting for approximately 20% of all fatal anaphylaxis cases. Quite often, a fatal reaction is a victim's first manifestation of HVA. Mastocytosis represents one of the most important risk factors for severe HVA. We analyzed patients with documented fatal HVA for the presence of underlying clonal mast cell disorder (cMCD). Here, we report three cases of fatal HVA, with undiagnosed underlying cMCD identified by the presence of the peripheral blood and/or bone marrow KIT p.D816V missense variant postmortem. In the first case, anaphylaxis was the initial episode and was fatal. In the other two cases, both patients were treated with specific venom immunotherapy (VIT), nevertheless, one died of HVA after VIT discontinuation, and the other during VIT; both patients had cardiovascular comorbidities and were taking beta-blockers and/or ACE inhibitors. Our results point to the importance of screening all high-risk individuals for underlying cMCD using highly sensitive molecular methods for peripheral blood KIT p.D816V variant detection, including severe HVA and possibly beekeepers, for proper management and the need for lifelong VIT to prevent unnecessary deaths. Patients at the highest risk of fatal HVA, with concomitant cardiovascular and cMCD comorbidities, might not be protected from field stings even during regular VIT. Therefore, two adrenaline autoinjectors and lifelong VIT, and possibly cotreatment with omalizumab, should be considered for high-risk patients to prevent fatal HVA episodes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Response to: 'Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered'.
- Author
-
Novembre, Elio, Gelsomino, Mariannita, Liotti, Lucia, Barni, Simona, Mori, Francesca, Giovannini, Mattia, Mastrorilli, Carla, Pecoraro, Luca, Saretta, Francesca, Castagnoli, Riccardo, Arasi, Stefania, Caminiti, Lucia, Klain, Angela, and del Giudice, Michele Miraglia
- Subjects
IMMUNOTHERAPY ,FOOD allergy ,ORAL drug administration ,MONOCLONAL antibodies ,ANAPHYLAXIS ,DISEASE risk factors ,CHILDREN - Published
- 2024
- Full Text
- View/download PDF
8. Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered.
- Author
-
Nicolardi, Francesca, Corona, Federica, Badina, Laura, Berti, Irene, and Barbi, Egidio
- Subjects
THERAPEUTIC use of monoclonal antibodies ,RISK assessment ,IMMUNOTHERAPY ,TERMINATION of treatment ,ORAL drug administration ,TREATMENT effectiveness ,DISEASE complications ,TREATMENT failure ,ANAPHYLAXIS ,DISEASE risk factors - Abstract
Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Fatal hymenoptera venom anaphylaxis by undetected clonal mast cell disorder: A better identification of high risk patients is needed.
- Author
-
Chatain, C., Sedillot, N., Thomas, M., Pernollet, M., Bocquet, A., Boccon-Gibod, I., Bouillet, L., and Leccia, M.T.
- Subjects
- *
HYMENOPTERA , *MAST cell disease , *ANAPHYLAXIS , *VENOM , *PANIC attacks - Abstract
Hymenoptera venom anaphylaxis is the most frequent cause of anaphylaxis and responsible for about 20% of all fatal anaphylaxis cases in adults. We report two cases of fatal hymenoptera venom anaphylaxis with undiagnosed underlying mastocytosis and review the risk factors for severe or fatal hymenoptera venom anaphylaxis, as well as the specificities of its association with mastocytosis. As hymenoptera venom allergic patients with underlying clonal mast cell disorder generally lack typical skin lesions of mastocytosis, its diagnosis can easily be missed, underscoring the importance and need for diagnostic strategies in order to correctly identify these patients. Predominant cardiovascular symptoms in the absence of urticaria or angioedema following an insect sting are suggestive of underlying clonal mast cell disorder, and should be distinguished from panic attack or vasovagal syncope. Similarly, an unexplained syncope or an "idiopathic" anaphylaxis might reveal mastocytosis or hereditary alpha-tryptasemia. Acute and basal serum tryptase measurements should always be integrated in the diagnostic work-up of an insect sting reaction or unexplained syncope or shock of any origin. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Fatal anaphylaxis in Italy: Analysis of cause‐of‐death national data, 2004‐2016.
- Author
-
Bilò, Maria Beatrice, Corsi, Alice, Martini, Matteo, Penza, Elena, Grippo, Francesco, and Bignardi, Donatella
- Subjects
- *
ANAPHYLAXIS , *VITAL records (Births, deaths, etc.) , *DEMOGRAPHIC characteristics , *DEATH certificates , *CAUSES of death - Abstract
Background: Epidemiological data on fatal anaphylaxis are underestimated worldwide. Few Italian data do exist. The aims of the study are to determine the anaphylaxis mortality rate in Italy and its associations with demographic characteristics (gender, age, and geographical distribution), and to investigate which are the most common triggers of fatal anaphylaxis. Material and methods: This is a descriptive study analyzing data reported to the National Register of Causes of Death database and managed by the Italian National Institute of Statistics for the years 2004‐2016. An analytical method was developed to identify all the ICD‐10 codes related to anaphylaxis deaths, which were divided into two classes: "Definite anaphylaxis deaths" and "Possible anaphylaxis deaths." Results: From 2004 through 2016, 392 definite anaphylaxis deaths and 220 possible anaphylaxis deaths were recorded. The average mortality rate for definite anaphylaxis, from 2004 to 2016, was 0.51 per million population per year. Definite fatal anaphylaxis was mostly due to the use of medications (73.7%), followed by unspecified causes (20.7%) and hymenoptera stings (5.6%). Concerning possible anaphylaxis deaths, the most common cause was venom‐stinging insect (51.4%). We did not find any data on food fatal anaphylaxis. Unspecified anaphylaxis accounted for 21%‐28% of all cases, underlining the difficulty in accurately ascertaining the causes of fatal anaphylaxis and therefore in assigning the proper ICD‐10 code. Conclusion: This is the first study of anaphylaxis‐related mortality coming from an official database of the whole Italian population. However, the actual number of deaths by anaphylaxis, and their related triggers, is probably underreported, mostly due to limitations of the current recording system, and to a poor allergy education. Corrective actions should be undertaken for the benefit of the Health System. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Incidence of Fatal Anaphylaxis: A Systematic Review of Observational Studies
- Author
-
Ana Gonzalez-Moreno, A Rosado-Ingelmo, S Perez-Codesido, E Pérez Fernández, N Alberti-Masgrau, E Grifol-Clar, A Nieto-Nieto, M Privitera-Torres, and Miguel A. Tejedor-Alonso
- Subjects
Pediatrics ,medicine.medical_specialty ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Mortality rate ,Immunology ,Population ,MEDLINE ,Fatal anaphylaxis ,Allergens ,medicine.disease ,medicine ,Humans ,Immunology and Allergy ,Observational study ,Prospective Studies ,Prospective cohort study ,education ,business ,Anaphylaxis ,Arthropod Venoms ,Retrospective Studies - Abstract
Background: Fatal anaphylaxis is very rare, with an incidence ranging from 0.5 to 1 deaths per million person-years. Objective: Based on a systematic review, we aimed to explain differences in the reported incidence of fatal anaphylaxis based on the methodological and demographic factors addressed in the various studies. Methods: We searched PubMed/MEDLINE, EMBASE, and the Web of Science for relevant retrospective and prospective cohort studies and registry studies that had assessed the anaphylaxis mortality rate for the population of a country or for an administrative region. The research strategy was based on combining the term “anaphylaxis” with “death”, “study design”, and “main outcomes” (incidence). Results: A total of 46 studies met the study criteria and included 16,541 deaths. The range of the anaphylaxis mortality rate for all causes of anaphylaxis was 0.002-2.51 deaths per million person-years. Fatal anaphylaxis due to food (range 0.002-0.29) was rarer than deaths due to drugs (range 0.004-0.56) or Hymenoptera venom (range 0.02-0.61). The frequency of deaths due to anaphylaxis by drugs increased during the study period (IRR per year, 1.02; 95%CI, 1.00-1.04). We detected considerable heterogeneity in almost all of the meta-analyses carried out. Conclusion: The incidence of fatal anaphylaxis is very low and differs according to the various subgroups analyzed. The studies were very heterogeneous. Fatal anaphylaxis due to food seems to be less common than fatal anaphylaxis due to drugs or Hymenoptera venom.
- Published
- 2022
- Full Text
- View/download PDF
12. Food‐induced fatal anaphylaxis: From epidemiological data to general prevention strategies.
- Author
-
Pouessel, Guillaume, Turner, Paul J., Worm, Margitta, Cardona, Victòria, Deschildre, Antoine, Beaudouin, Etienne, Renaudin, Jean‐Marie, Demoly, Pascal, and Tanno, Luciana K.
- Subjects
- *
ANAPHYLAXIS , *DEATH rate , *ADRENALINE , *IMMUNOTHERAPY , *ALLERGY in children - Abstract
Summary: Background: Anaphylaxis hospitalizations are increasing in many countries, in particular for medication and food triggers in young children. Food‐related anaphylaxis remains an uncommon cause of death, but a significant proportion of these are preventable. Aim: To review published epidemiological data relating to food‐induced anaphylaxis and potential risk factors of fatal and/or near‐fatal anaphylaxis cases, in order to provide strategies to reduce the risk of severe adverse outcomes in food anaphylaxis. Methods: We identified 32 published studies available in MEDLINE (1966‐2017), EMBASE (1980‐2017), CINAHL (1982‐2017), using known terms and synonyms suggested by librarians and allergy specialists. Results: Young adults with a history of asthma, previously known food allergy particularly to peanut/tree nuts are at higher risk of fatal anaphylaxis reactions. In some countries, cow's milk and seafood/fish are also becoming common triggers of fatal reactions. Delayed adrenaline injection is associated with fatal outcomes, but timely adrenaline alone may be insufficient. There is still a lack of evidence regarding the real impact of these risk factors and co‐factors (medications and/or alcohol consumption, physical activities, and mast cell disorders). Conclusions: General strategies should include optimization of the classification and coding for anaphylaxis (new ICD 11 anaphylaxis codes), dissemination of international recommendations on the treatment of anaphylaxis, improvement of the prevention in food and catering areas, and dissemination of specific policies for allergic children in schools. Implementation of these strategies will involve national and international support for ongoing local efforts in relationship with networks of centres of excellence to provide personalized management (which might include immunotherapy) for the most at‐risk patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Chemotherapy‐induced anaphylaxis and fatal anaphylaxis in the United States: Incidence and risk factors
- Author
-
Ricardo Zwiener, Yenny A. Moreno Vanegas, Lyda Cuervo-Pardo, Alexei Gonzalez-Estrada, Ismael Carrillo-Martin, Leyla Bojanini, and Dan Morgenstern-Kaplan
- Subjects
medicine.medical_specialty ,Clinical immunology ,business.industry ,Incidence ,Incidence (epidemiology) ,Immunology ,Drug allergy ,Fatal anaphylaxis ,Antineoplastic Agents ,Allergens ,medicine.disease ,Dermatology ,United States ,Chemotherapy induced ,Risk Factors ,Epidemiology ,medicine ,Humans ,Immunology and Allergy ,business ,Anaphylaxis ,Food Hypersensitivity - Published
- 2021
- Full Text
- View/download PDF
14. Rational Development of Antigen-Specific Therapies for Type 1 Diabetes
- Author
-
Fousteri, Georgia, Bresson, Damien, Von Herrath, Matthias, Shurin, Michael R., editor, and Smolkin, Yuri S., editor
- Published
- 2007
- Full Text
- View/download PDF
15. Differences Between Central and Peripheral Postmortem Tryptase Levels
- Author
-
Paul Morrow, Charley Glenn, Simon Stables, Kilak Kesha, Rexson Tse, Ugo Da Broi, Cristian Palmiere, Jack Garland, and Benjamin Ondruschka
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Femoral vein ,Vena Cava, Inferior ,Tryptase ,Inferior vena cava ,Specimen Handling ,Pathology and Forensic Medicine ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine.artery ,medicine ,Humans ,Prospective Studies ,030216 legal & forensic medicine ,Anaphylaxis ,Aorta ,Aged ,biology ,business.industry ,Fatal anaphylaxis ,Femoral Vein ,Forensic Medicine ,Middle Aged ,Peripheral ,medicine.vein ,Postmortem Changes ,cardiovascular system ,Cardiology ,biology.protein ,Arterial blood ,Female ,Tryptases ,business ,Biomarkers - Abstract
Postmortem tryptase is a commonly used biochemical test to aid in the diagnosis of fatal anaphylaxis, which is currently recommended to be sampled from peripheral (femoral) veins because of a research showing comparatively elevated levels from central blood sources. Previous studies have used nonstandardized or nondocumented sampling methods; however, more recent research demonstrates that tryptase levels may vary depending on the sampling method. This study used the recommended sampling method of aspirating the femoral vein after clamping and compared in a pairwise comparison with aspiration of central venous and arterial blood sources (inferior vena cava and aorta) in 2 groups of 25 nonanaphylactic deaths. We found no statistically significant differences in postmortem tryptase between central and femoral vein blood; however, sporadic outliers in central blood (particularly aortic blood reaching levels above documented cutoffs for fatal anaphylaxis) were observed. Our findings provide evidence for the existing recommendations that femoral vein blood remains the preferred sample for postmortem tryptase over central blood.
- Published
- 2020
- Full Text
- View/download PDF
16. Venom immunotherapy in Europe and the United States
- Author
-
Leonardo Antonicelli, Matteo Martini, M. Beatrice Bilò, Alice Corsi, and Chiara Tontini
- Subjects
medicine.medical_specialty ,Allergy ,business.industry ,medicine.medical_treatment ,Treatment duration ,Fatal anaphylaxis ,Venom ,Immunotherapy ,Venom immunotherapy ,medicine.disease_cause ,medicine.disease ,complex mixtures ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Allergen ,030228 respiratory system ,Insect venom allergy ,Immunology and Allergy ,Medicine ,business ,Intensive care medicine - Abstract
Hymenoptera stings are accountable for significant morbidity and deterioration in health-related quality of life due to the allergic reactions they cause, the most severe of which can culminate in fatal anaphylaxis. The availability of high quality venom extracts for use in the diagnosis and treatment of insect venom allergy has improved the prognosis and the health-related quality of life of venom-allergic patients. All over the world subcutaneous venom immunotherapy is currently the most effective form of allergen-based immunotherapy with an early, sustained and long-term efficacy. Even though the type of insect responsible for allergic reactions may be different from Europe and US and therefore also the type of extract, nevertheless indications and contraindications are quite similar, as well as treatment protocols and treatment duration. However, neither the efficacy nor the safety of the treatment are optimal, especially with regard to bee venom immunotherapy, and so there is considerable room for further improvement in these important areas. This review presents the current practice of venom immunotherapy in Europe and United States discussed at the EAACI (European Academy of Allergy and Clinical Immunology) Allergy School on Insect Venom held in Groningen in April 2019.
- Published
- 2020
- Full Text
- View/download PDF
17. Increases in anaphylaxis fatalities in Australia from 1997 to 2013.
- Author
-
Mullins, R. J., Wainstein, B. K., Barnes, E. H., Liew, W. K., and Campbell, D. E.
- Subjects
- *
ANAPHYLAXIS , *INSECT bites & stings , *BLOOD products , *FOOD allergy , *COMORBIDITY , *SUDDEN death ,RISK factors - Abstract
Background Recent epidemiological studies indicate increases in Australian, UK and US hospital anaphylaxis admission rates. Objectives The aim of this study was to determine whether Australian anaphylaxis fatalities are increasing in parallel and to examine the characteristics of fatalities recorded in the National Coronial Information System ( NCIS). Methods Time trends in Australian anaphylaxis fatalities were examined using data derived from the Australian Bureau of Statistics ( ABS) 1997-2013 and the NCIS 2000-2013, the latter providing additional information to verify cause and identify risk factors. Results The ABS recorded 324 anaphylaxis fatalities by cause: unspecified ( n = 205); medication ( n = 52); insect stings/tick bites ( n = 41); food ( n = 23); and blood products ( n = 3). From 1997 to 2013, all-cause fatal anaphylaxis rates increased by 6.2%/year (95% CI: 3.8-8.6%, P < 0.0001) or from 0.054% to 0.099/105 population. Fatal food anaphylaxis increased by 9.7%/year (95% CI: 0.25-20%, P = 0.04) and unspecified anaphylaxis deaths by 7.8% (95% CI: 4.6-11.0, P < 0.0001). There was an insignificant change in medication-related fatalities (5.6% increase/year; 95% CI: 0.3% decrease to 11.8% increase, P = 0.06), and sting/bite fatalities remained unchanged. Hospital anaphylaxis admission rates for all-cause, food, unspecified and medication anaphylaxis increased at rates of 8%, 10%, 4.4% and 6.8%/year, respectively. A total of 147 verified NCIS deaths were examined in detail: medication- and sting/bite-related fatalities occurred predominantly in older individuals with multiple comorbidities. Upright posture after anaphylaxis was associated with risk of sudden death (all causes). Seafood (not nuts) was the most common trigger for food-related anaphylaxis deaths. Conclusions Australian anaphylaxis fatality rates (most causes) have increased over the last 16 years, contrasting with UK- and US-based studies that describe overall lower and static overall anaphylaxis fatality rates (0.047-0.069/105 population). [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Near-fatal anaphylaxis with Kounis syndrome caused by Argas reflexus bite: a case report
- Author
-
Cristoforo Incorvaia and Elisa Boni
- Subjects
lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,Allergy ,Immunology ,Tick bites ,Kounis syndrome ,Case Report ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Allergen ,parasitic diseases ,medicine ,Immunology and Allergy ,Molecular Biology ,Anaphylaxis ,030201 allergy ,Pigeon tick ,Medical treatment ,business.industry ,Fatal anaphylaxis ,Argas reflexus ,medicine.disease ,Dermatology ,030228 respiratory system ,business ,lcsh:RC581-607 - Abstract
Background The pigeon tick Argas reflexus is a temporary parasite of pigeons. It bites during night hours and lies briefly on its prey, as long as it takes the blood meal. When pigeons are not accessible, ticks look for other hosts, invading nearby flats and biting humans. Case presentation We present the case of a woman aged 46 years who experienced severe anaphylaxis during the night which required emergency medical treatment, tracheal intubation and hospitalization in intensive care unit. Kounis syndrome was documented by transient ST depression and elevation of troponin. The allergological work up ruled out hypersensitivity to drugs, latex and foods containing alpha-gal, which is a cause of anaphylaxis. Basal serum tryptase was in normal range (8.63 ng/ml). When questioned about the presence of ticks, the patient brought into view various specimens of ticks that were recognized by an entomologist as Argas reflexus. Conclusions An in vitro diagnosis of allergy to Argas reflexus is currently not feasible because, though the major allergen Arg r 1 has been isolated, allergen extracts are not commercially available. Therefore, the diagnosis of anaphylaxis from Argas reflexus, when other causes of anaphylaxis are excluded, must rely only on history and clinical findings, as well as on the presence of pigeons and/or pigeon ticks in the immediate domestic environment.
- Published
- 2020
- Full Text
- View/download PDF
19. Risk factors and indicators of severe systemic insect sting reactions
- Subjects
mastocytosis ,EUROPEAN ACADEMY ,BASAL SERUM TRYPTASE ,KIT D816V MUTATION ,tryptase ,venom ,INDUCED ANAPHYLAXIS ,FATAL ANAPHYLAXIS ,PLATELET-ACTIVATING-FACTOR ,CONVERTING ENZYME-INHIBITORS ,age ,MAST-CELL DISORDERS ,BEE VENOM ,medication ,HYMENOPTERA VENOM ALLERGY - Abstract
Hymenoptera venom allergy ranks among the top three causes of anaphylaxis worldwide, and approximately one-quarter of sting-induced reactions are classified as severe. Fatal sting reactions are exceedingly rare, but certain factors may entail a considerably higher risk. Delayed administration of epinephrine and upright posture are situational risk factors which may determine an unfavorable outcome of the acute anaphylactic episode and should be addressed during individual patient education. Systemic mastocytosis and senior age are major, unmodifiable long-term risk factors and thus reinforce the indication for venom immunotherapy. Vespid venom allergy and male sex likewise augment the risk of severe or even fatal reactions. Further studies are required to assess the impact of specific cardiovascular comorbidities. Available data regarding potential effects of beta-blockers and/or ACE inhibitors in coexisting venom allergy are inconclusive and do not justify recommendations to discontinue guideline-directed antihypertensive treatment. The absence of urticaria/angioedema during sting-induced anaphylaxis is indicative of a severe reaction, serum tryptase elevation, and mast cell clonality. Determination of basal serum tryptase levels is an established diagnostic tool for risk assessment in Hymenoptera venom-allergic patients. Measurement of platelet-activating factor acetylhydrolase activity represents a complementary approach but is not available for routine diagnostic use.
- Published
- 2020
20. FATAL ANAPHYLAXIS TO Jaguajir rochae (BORELLI, 1910) (SCORPIONES, BUTHIDAE) IN BRAZIL: A CASE REPORT
- Author
-
Relrison Dias Ramalho, Carlos Roberto de Medeiros, Iva Maria Lima Araujo Melo, Maria Apolônia da Costa Gadelha, Maria Mercedes Vieira Bezerra, Ivan Eduardo de Oliveira Filho, and Pedro Pereira de Oliveira Pardal
- Subjects
Allergy ,medicine.medical_specialty ,General Immunology and Microbiology ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Scorpion ,Fatal anaphylaxis ,medicine.disease ,biology.organism_classification ,Dermatology ,Malaise ,Sting ,Infectious Diseases ,Buthidae ,biology.animal ,medicine ,medicine.symptom ,business ,Envenomation ,Anaphylaxis - Abstract
A 44-year-old healthy farmer, was stung by a scorpion on his right hand while preparing soil for planting in the Caatinga area (a large area in the north-east of Brazil characterized by semiarid scrub forest), in the Catarina Municipality countryside, Ceará State, Brazil. According to the reports of carers and family members, the patient initially reported mild pain at the site of the sting, but within a few minutes he developed malaise, pruritus in the body and throat, edema in the nostrils, and a dry mouth which led to looking for water to drink. It rapidlyevolved into sphincter, urinary and fecal release, salivation and a convulsive episode with loss of the senses. He was dead on arrival at Catarina Municipality Hospital emergency department.The necroscopic report indicated suffocation due to glottal edema and acute lung edema as the “cause of death”. The animal which caused the accident was under a rock that the patient was manipulating at the time of the incident, and has been identified by experts as Jaguajir rochae (Borelli, 1910) scorpion species, formerly synonymized Rhopalurus rochae. This is the first report of a fatality due to an allergic reaction to the venom of this species. This leads to the possibility that deaths caused by stings from other scorpion species may be due to anaphylaxis, whose symptoms in some situations may be confused with severe envenomation. KEY WORDS: Jaguajir rochae; scorpionism; anaphylaxis; allergy
- Published
- 2019
- Full Text
- View/download PDF
21. Risk factors and indicators of severe systemic insect sting reactions
- Author
-
Gunter J. Sturm, Patrizia Bonadonna, Axel Trautmann, Joanna N G Oude Elberink, and Johanna Stoevesandt
- Subjects
Male ,0301 basic medicine ,EUROPEAN ACADEMY ,medicine.medical_specialty ,Allergy ,BASAL SERUM TRYPTASE ,KIT D816V MUTATION ,Immunology ,tryptase ,venom ,INDUCED ANAPHYLAXIS ,FATAL ANAPHYLAXIS ,Tryptase ,Venom ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,MAST-CELL DISORDERS ,medicine ,Animals ,Humans ,Immunology and Allergy ,Systemic mastocytosis ,Anaphylaxis ,Arthropod Venoms ,mastocytosis ,Angioedema ,biology ,business.industry ,Insect Bites and Stings ,medicine.disease ,Hymenoptera ,PLATELET-ACTIVATING-FACTOR ,Sting ,CONVERTING ENZYME-INHIBITORS ,030104 developmental biology ,age ,030228 respiratory system ,biology.protein ,BEE VENOM ,medication ,HYMENOPTERA VENOM ALLERGY ,medicine.symptom ,business ,Risk assessment - Abstract
Hymenoptera venom allergy ranks among the top three causes of anaphylaxis worldwide, and approximately one-quarter of sting-induced reactions are classified as severe. Fatal sting reactions are exceedingly rare, but certain factors may entail a considerably higher risk. Delayed administration of epinephrine and upright posture are situational risk factors which may determine an unfavorable outcome of the acute anaphylactic episode and should be addressed during individual patient education. Systemic mastocytosis and senior age are major, unmodifiable long-term risk factors and thus reinforce the indication for venom immunotherapy. Vespid venom allergy and male sex likewise augment the risk of severe or even fatal reactions. Further studies are required to assess the impact of specific cardiovascular comorbidities. Available data regarding potential effects of beta-blockers and/or ACE inhibitors in coexisting venom allergy are inconclusive and do not justify recommendations to discontinue guideline-directed antihypertensive treatment. The absence of urticaria/angioedema during sting-induced anaphylaxis is indicative of a severe reaction, serum tryptase elevation, and mast cell clonality. Determination of basal serum tryptase levels is an established diagnostic tool for risk assessment in Hymenoptera venom-allergic patients. Measurement of platelet-activating factor acetylhydrolase activity represents a complementary approach but is not available for routine diagnostic use.
- Published
- 2019
- Full Text
- View/download PDF
22. Updated anaphylaxis guidelines: management in infants and children
- Author
-
Preeti Joshi, Katie Frith, Sandra Vale, Lara S. Ford, and Jill Smith
- Subjects
Allergy ,Clinical immunology ,business.industry ,Fatal anaphylaxis ,medicine.disease ,allergy ,Article ,adrenaline (epinephrine) injector device ,Epinephrine ,adrenaline (epinephrine) ,Anesthesia ,medicine ,anaphylaxis ,Pharmacology (medical) ,Acute management ,business ,Anaphylaxis ,medicine.drug - Abstract
SUMMARY Severe allergic reactions (anaphylaxis) are unpredictable, and initial signs of what could be fatal anaphylaxis can be mild Adrenaline (epinephrine) remains the first-line drug of choice for the acute management of anaphylaxis and should be administered early There are no contraindications to intramuscular adrenaline in the treatment of anaphylaxis Correct positioning of the patient is vital as death can occur within minutes if a patient stands, walks or sits up suddenly. Position the patient correctly first and then promptly administer intramuscular adrenaline Updated guidelines by the Australasian Society of Clinical Immunology and Allergy now recommend that the 0.15 mg adrenaline injector device may be prescribed for infants and children weighing 7.5–10 kg. The recommendation to use the 0.3 mg adrenaline injector device for those over 20 kg remains unchanged The adrenaline doses in Australian Prescriber’s anaphylaxis wallchart remain valid
- Published
- 2021
23. Fatal anaphylaxis to intravenous ondansetron: A case report
- Author
-
Kalyan Sapkota and Roshan Bhagat
- Subjects
medicine.medical_specialty ,Medicine (General) ,fatal ,business.industry ,Fatal anaphylaxis ,General Medicine ,Case Reports ,medicine.disease ,Ondansetron ,R5-920 ,ondansetron ,medicine ,anaphylaxis ,Medicine ,case report ,Intensive care medicine ,business ,Adverse effect ,Anaphylaxis ,medicine.drug - Abstract
The safety and efficacy of ondansetron has led to its wider clinical use and this could increase unusual serious adverse events. Therefore, we emphasize the need for cautious use of ondansetron and beware and prepare for unusual adverse events.
- Published
- 2021
24. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
- Author
-
Massimo Triggiani, Clive Grattan, Carsten Bindslev-Jensen, Joseph H. Butterfield, Melody C. Carter, Dean D. Metcalfe, Mariana Castells, Lawrence B. Schwartz, Hans-Peter Horny, Knut Brockow, Cem Akin, Andreas Reiter, Sigurd Broesby-Olsen, Peter Valent, Mohamad Jawhar, Juliana Schwaab, Olivier Hermine, Iván Álvarez-Twose, Jason Gotlib, Bogusław Nedoszytko, Wolfgang R. Sperr, Theo Gülen, Michel Arock, Marek Niedoszytko, Hanneke Oude Elberink, Patrizia Bonadonna, Karin Hartmann, Vito Sabato, Karl Sotlar, Alberto Orfao, Frank Siebenhaar, Deepti Radia, Roberta Zanotti, and Groningen Research Institute for Asthma and COPD (GRIAC)
- Subjects
Allergy ,Pediatrics ,SYMPTOMS ,Hypersensitivity reactions ,0302 clinical medicine ,Pandemic ,Immunology and Allergy ,Mast Cells ,030212 general & internal medicine ,Systemic mastocytosis ,HYPERSENSITIVITY ,RISK ,Adverse reaction to medications ,COVID-19 ,Mast cell diseases ,Mastocytosis ,Vaccine ,Vaccination ,SYSTEMIC MASTOCYTOSIS ,Vaccine Covid 19 ,Clonal Mast Cell Disease ,Mastocytosis/epidemiology ,Anaphylaxis ,medicine.medical_specialty ,COVID-19 Vaccines ,DISORDERS ,Anaphylaxis/epidemiology ,FATAL ANAPHYLAXIS ,macromolecular substances ,CLASSIFICATION ,Competence (law) ,Special Article ,03 medical and health sciences ,medicine ,MANAGEMENT ,Humans ,SARS-CoV-2 ,business.industry ,Cutaneous Mastocytosis ,medicine.disease ,PREVENTION ,United States ,030228 respiratory system ,Concomitant ,Human medicine ,HYMENOPTERA VENOM ALLERGY ,business ,Allergic reaction to Vaccine - Abstract
Mastocytosis is a neoplasm characterized by an accumulation of mast cells in various organs and increased risk for severe anaphylaxis in patients with concomitant allergies. Coronavirus disease 2019 (COVID-19) is a pandemic that is associated with a relatively high rate of severe lung disease and mortality. The mortality is particularly high in those with certain comorbidities and increases with age. Recently, several companies have developed an effective vaccination against COVID-19. Although the reported frequency of severe side effects is low, there is an emerging discussion about the safety of COVID-19 vaccination in patients with severe allergies and mastocytosis. However, even in these patients, severe adverse reactions are rare. We therefore recommend the broad use of COVID-19 vaccination in patients with mastocytosis on a global basis. The only well-established exception is a known or suspected allergy against a constituent of the vaccine. Safety measures, including premedication and postvaccination observation, should be considered in all patients with mastocytosis, depending on the individual personal risk and overall situation in each case. The current article provides a summary of published data, observations, and expert opinion that form the basis of these recommendations.
- Published
- 2021
- Full Text
- View/download PDF
25. Anaphylaxis refractory to intra-muscular adrenaline during in-hospital food challenges: a case series and proposed management
- Author
-
Michel Erlewyn-Lajeunesse, Abigail Macleod, Paul Turner, Susan Edees, Sarah Burrell, Cherry Alviani, Graham Roberts, Medical Research Council (MRC), and National Institute for Health Research
- Subjects
Male ,0301 basic medicine ,Allergy ,Drug Resistance ,CHILDREN ,GUIDELINES ,0302 clinical medicine ,Anti-Allergic Agents ,Immunology and Allergy ,EPIDEMIOLOGY ,Child ,Infusions, Intravenous ,UNITED-KINGDOM ,RISK ,Oral food challenge ,Fatal anaphylaxis ,EPINEPHRINE ,Hypersensitivity reaction ,Treatment Outcome ,1107 Immunology ,FATALITIES ,Female ,Life Sciences & Biomedicine ,Food Hypersensitivity ,Anaphylaxis ,medicine.medical_specialty ,Adolescent ,Immunology ,Immunologic Tests ,Injections, Intramuscular ,1117 Public Health and Health Services ,03 medical and health sciences ,Refractory ,Predictive Value of Tests ,Food allergy ,oral food challenge ,medicine ,anaphylaxis ,Humans ,Intensive care medicine ,Adverse effect ,food allergy ,Science & Technology ,adrenaline ,business.industry ,Allergens ,medicine.disease ,030104 developmental biology ,030228 respiratory system ,ALLERGIC REACTIONS ,1111 Nutrition and Dietetics ,business - Abstract
Background: anaphylaxis is a severe, systemic hypersensitivity reaction that can be potentially life-threatening. Anaphylaxis during oral food challenge is not uncommon and can usually be effectively managed with intramuscular adrenaline as first line treatment. Although very rare, fatal anaphylaxis during in-hospital food challenge has been reported. Objective: we describe our experience of cases of refractory anaphylaxis at in-hospital challenge and propose a framework for escalation of treatment in such cases using intravenous infusion of adrenaline which has been adopted for widespread use elsewhere. Methods: we present four patients who all experienced severe life-threatening anaphylaxis, refractory to intramuscular adrenaline treatment, during supervised oral food challenges. Patient data were collected from contemporaneous notes, and patient consent was obtained. Results: in all four cases, the anaphylaxis reactions were amenable to treatment with low-dose intravenous adrenaline, with no reported adverse effects. Conclusion and clinical relevance: these cases demonstrate the need for clinicians undertaking higher risk allergen challenges to be able to manage cases of severe anaphylaxis refractory to intramuscular adrenaline, and to consider a framework for managing these reactions. While peripheral intravenous adrenaline infusions should always be initiated only in conjunction with expert input, the protocol suggested is simple enough to be undertaken within the hospital environment while more experienced support is obtained.
- Published
- 2020
26. Attention2AngioGAN: Synthesizing Fluorescein Angiography from Retinal Fundus Images using Generative Adversarial Networks
- Author
-
Sharif Amit Kamran, Stewart Lee Zuckerbrod, Alireza Tavakkoli, and Khondker Fariha Hossain
- Subjects
FOS: Computer and information sciences ,Computer science ,Computer Vision and Pattern Recognition (cs.CV) ,Computer Science - Computer Vision and Pattern Recognition ,010501 environmental sciences ,Fundus (eye) ,01 natural sciences ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Robustness (computer science) ,FOS: Electrical engineering, electronic engineering, information engineering ,medicine ,Computer vision ,0105 earth and related environmental sciences ,medicine.diagnostic_test ,business.industry ,Image and Video Processing (eess.IV) ,Photography ,Fundus photography ,Fatal anaphylaxis ,Retinal ,Electrical Engineering and Systems Science - Image and Video Processing ,Fluorescein angiography ,eye diseases ,chemistry ,Angiography ,Artificial intelligence ,business - Abstract
Fluorescein Angiography (FA) is a technique that employs the designated camera for Fundus photography incorporating excitation and barrier filters. FA also requires fluorescein dye that is injected intravenously, which might cause adverse effects ranging from nausea, vomiting to even fatal anaphylaxis. Currently, no other fast and non-invasive technique exists that can generate FA without coupling with Fundus photography. To eradicate the need for an invasive FA extraction procedure, we introduce an Attention-based Generative network that can synthesize Fluorescein Angiography from Fundus images. The proposed gan incorporates multiple attention based skip connections in generators and comprises novel residual blocks for both generators and discriminators. It utilizes reconstruction, feature-matching, and perceptual loss along with adversarial training to produces realistic Angiograms that is hard for experts to distinguish from real ones. Our experiments confirm that the proposed architecture surpasses recent state-of-the-art generative networks for fundus-to-angio translation task., 8 pages, 4 figures, 2 tables
- Published
- 2020
27. Fatal anaphylaxis from a second amoxicillin/clavulanic acid provocation after a prior negative provocation
- Author
-
Aree Jameekornrak Taweechue, Piyawut Kreetapirom, Mongkhon Sompornrattanaphan, Orathai Theankeaw, Chamard Wongsa, and Torpong Thongngarm
- Subjects
medicine.medical_specialty ,Amoxicillin/clavulanic acid ,business.industry ,Provocation test ,Amoxicillin ,Fatal anaphylaxis ,Amoxicillin-Potassium Clavulanate Combination ,Dermatology ,Anti-Bacterial Agents ,Clavulanic acid ,Humans ,Immunology and Allergy ,Medicine ,business ,Anaphylaxis ,Clavulanic Acid ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
28. Anaphylactic shock with intravenous furosemide: a rare undesired effect
- Author
-
Vandana Seth, Divya Gahlot, Manisha Manohar, and Rittick Talukdar
- Subjects
medicine.drug_class ,business.industry ,medicine.medical_treatment ,fatal outcome ,Antibiotics ,lcsh:R ,Furosemide ,Fatal anaphylaxis ,lcsh:Medicine ,Pulmonary edema ,medicine.disease ,Care setting ,sulphonamides ,Anesthesia ,medicine ,Anaphylactic shock ,anaphylaxis ,furosemide ,Diuretic ,business ,Anaphylaxis ,medicine.drug - Abstract
Furosemide is a potent diuretic, with structural similarity to sulphonamide antibiotics. Its relative safety profile is one of the reasons to account for its widespread use. We report a rare case of fatal anaphylaxis with intravenous furosemide administered in our critical care settings for pulmonary edema. Chemical similarity of furosemide with sulphonamide antibiotics shares the possibility of similar allergic side effects. Thus, a more careful clinical use of furosemide, especially if administered intravenous should be kept in mind to avoid such catastrophic events.
- Published
- 2020
29. Myths, facts and controversies in the diagnosis and management of anaphylaxis
- Author
-
Katherine Anagnostou, Paul Turner, and Medical Research Council (MRC)
- Subjects
medicine.medical_specialty ,Allergy ,Allergic reaction ,education ,VACCINE ,FATAL ANAPHYLAXIS ,CHILDREN ,Review ,GUIDELINES ,Pediatrics ,1117 Public Health and Health Services ,AUTOINJECTORS ,03 medical and health sciences ,0302 clinical medicine ,Food allergy ,030225 pediatrics ,Food anaphylaxis ,ADOLESCENTS ,anaphylaxis ,medicine ,Humans ,Intensive care medicine ,health care economics and organizations ,RISK ,food allergy ,Science & Technology ,adrenaline ,Health professionals ,business.industry ,FOOD ANAPHYLAXIS ,Fatal anaphylaxis ,1103 Clinical Sciences ,vaccines ,allergy ,medicine.disease ,Patient Care Management ,3. Good health ,Pediatrics, Perinatology and Child Health ,1114 Paediatrics and Reproductive Medicine ,ALLERGIC REACTIONS ,HOSPITALIZATIONS ,business ,Life Sciences & Biomedicine ,Anaphylaxis - Abstract
Anaphylaxis is a serious systemic allergic reaction that is rapid in onset and may cause death. Despite numerous national and international guidelines and consensus statements, common misconceptions still persist in terms of diagnosis and appropriate management, both among healthcare professionals and patient/carers. We address some of these misconceptions and highlight the optimal approach for patients who experience potentially life-threatening allergic reactions.
- Published
- 2018
- Full Text
- View/download PDF
30. Food allergy and anaphylaxis
- Author
-
David Yue, Amanda Ciccolini, Susan Waserman, and Ernie Avilla
- Subjects
avoidance ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Allergic reaction ,medicine.medical_treatment ,Signs and symptoms ,Review ,allergic reaction ,03 medical and health sciences ,0302 clinical medicine ,Food allergy ,030225 pediatrics ,Immunology and Allergy ,Medicine ,epinephrine ,Intensive care medicine ,Desensitization (medicine) ,business.industry ,food ,Fatal anaphylaxis ,trigger ,medicine.disease ,Increased risk ,Epinephrine ,030228 respiratory system ,immunotherapy ,business ,Anaphylaxis ,medicine.drug - Abstract
Anaphylaxis is a severe and potentially life-threatening allergic reaction. There are numerous potential causes, with food allergy being the leading cause in children and the focus of this review. Most reactions involve an IgE-mediated mechanism, although non-IgE-mediated and nonimmunologic reactions can occur. Various cofactors to be discussed can place certain individuals at an increased risk of severe or fatal anaphylaxis. The clinical manifestations of anaphylaxis are broad and may involve multiple body systems. Diagnosis of food-related anaphylaxis is primarily based on signs and symptoms and supported, wherever possible, by identification and confirmation of a culprit food allergen. First-line treatment of anaphylaxis is intramuscular administration of epinephrine. Long-term management is generally focused on strict allergen avoidance and more recently on food desensitization using immunotherapy. This review provides an overview of anaphylaxis with a specific focus on food allergy.
- Published
- 2018
- Full Text
- View/download PDF
31. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities
- Author
-
Benjamin T Prince, David R. Stukus, and Irene Mikhail
- Subjects
Pulmonary and Respiratory Medicine ,food allergy ,medicine.medical_specialty ,emergency department ,business.industry ,Anaphylactic reaction ,Fatal anaphylaxis ,Review ,Emergency department ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Epinephrine ,030228 respiratory system ,Food allergy ,030225 pediatrics ,anaphylaxis ,medicine ,Immunology and Allergy ,Effective treatment ,epinephrine ,Intensive care medicine ,business ,Anaphylaxis ,medicine.drug - Abstract
Epinephrine is the only effective treatment for anaphylaxis but studies routinely show underutilization. This is especially troubling given the fact that fatal anaphylaxis has been associated with delayed administration of epinephrine. Many potential barriers exist to the proper use of epinephrine during an anaphylactic reaction. This article will explore both patient-and physician-related factors, as well as misconceptions that all contribute to the underuse of epinephrine for the treatment of anaphylaxis.
- Published
- 2018
- Full Text
- View/download PDF
32. Corrigendum to 'Fatal anaphylaxis due to alpha-gal syndrome after initial cetuximab administration: The first forensic case report' [Legal Med. 51 (2021) 101878]
- Author
-
Shuheng Wen, Hajime Hikino, Kana Unuma, Koichi Uemura, and Yuko Chinuki
- Subjects
Issues, ethics and legal aspects ,medicine.medical_specialty ,Cetuximab ,business.industry ,medicine ,Alpha (ethology) ,Fatal anaphylaxis ,business ,Dermatology ,Pathology and Forensic Medicine ,medicine.drug - Published
- 2021
- Full Text
- View/download PDF
33. Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis
- Author
-
Byrthe J. P. R. Vos, Jasper J. van Doormaal, Joanne N.G. Oude Elberink, Bjorn van Anrooij, Anthony E.J. Dubois, and Groningen Research Institute for Asthma and COPD (GRIAC)
- Subjects
Male ,0301 basic medicine ,Allergy ,BASAL SERUM TRYPTASE ,Wasps ,Wasp Venoms ,Venom ,Immunoglobulin E ,BLOOD MONONUCLEAR-CELLS ,Fatal Outcome ,0302 clinical medicine ,Immunology and Allergy ,Systemic mastocytosis ,biology ,Area under the curve ,Fatal anaphylaxis ,Middle Aged ,SINGLE-CENTER EXPERIENCE ,Specific IgE ,Female ,SENSITIVITY ,Yellow jacket ,Adult ,Risk ,medicine.medical_specialty ,Epinephrine ,INDOLENT SYSTEMIC MASTOCYTOSIS ,Sensitivity and Specificity ,Sensitization ,03 medical and health sciences ,Mastocytosis, Systemic ,Urticaria Pigmentosa ,medicine ,Animals ,Humans ,IMMUNOTHERAPY ,Anaphylaxis ,Natural course ,business.industry ,fungi ,Insect Bites and Stings ,NATURAL-HISTORY ,Allergens ,C-KIT MUTATION ,medicine.disease ,Dermatology ,Hymenoptera ,Ves v 5 ,030104 developmental biology ,030228 respiratory system ,Desensitization, Immunologic ,HISTAMINE METABOLITES ,Immunology ,biology.protein ,Tryptases ,HYMENOPTERA VENOM ALLERGY ,business - Abstract
BACKGROUND: Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kU(A)/L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis.OBJECTIVE: To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM.METHODS: All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313).RESULTS: A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kU(A)/L; P CONCLUSIONS: The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kU(A)/L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kU(A)/L.
- Published
- 2017
- Full Text
- View/download PDF
34. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940 000 inhabitants of the Swiss Canton Bern.
- Author
-
Helbling, A., Hurni, T., Mueller, U. R., and Pichler, W. J.
- Subjects
- *
ANAPHYLAXIS , *HYMENOPTERA , *ALLERGIES , *VENOM , *EPIDEMIOLOGY - Abstract
Diagnosis of anaphylaxis is clinically based and usually straightforward. However, data on the epidemiology of anaphylaxis, particularly the most profound and life-threatening form such as anaphylactic shock are limited and thought to be under-reported. The primary aim of this study was to investigate the incidence and the causes of severe anaphylaxis with circulatory signs in the Canton Bern, which comprises about 940 000 inhabitants or approximately one-seventh of the population of Switzerland. During a 3-year period, 1 January 1996 to 31 December 1998, all medical records (7739 documents) from the two allergy clinics of the Canton Bern have been reviewed. In addition, all seven board-certified specialists of the Foederatio Medicorum Helveticorum (FMH) in Allergology and Clinical Immunology of this Canton as well as all 17 hospitals with emergency units of this area have been contacted for cases with an anaphylactic event not referred to the allergy clinics. Overall, 226 individuals, 106 females (47%) with a mean age of 41 years (range, 5–74 years) and 120 males (53%) with a mean age of 38 years (8 months–83 years) were diagnosed as having presented generalized, life-threatening anaphylaxis with circulatory symptoms. Altogether, these patients experienced 246 episodes of severe systemic reactions. In addition, death due to anaphylaxis occurred in three subjects. The annual incidence of anaphylaxis per 100 000 inhabitants per year ranged between 7.9 and 9.6 cases. Hymenoptera stings (58.8%), drugs (18.1%), and foods (10.1%) were the most commonly identified culprits for anaphylaxis. In 5.3% of all anaphylactic events, the cause could not be identified. The incidence rate of severe life-threatening anaphylaxis with circulatory signs in the Canton Bern, Switzerland, with 7.9–9.6 per 100 000 inhabitants per year is comparable to the findings of other epidemiological investigations. In most events, a causal agent or allergen could be identified by a careful allergological examination. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
35. Fatal food-induced anaphylaxis: determination of tryptase and specific IgE on cadaveric blood samples. What else for a better methodological standard?
- Author
-
Matteo Scopetti, Vittorio Fineschi, Alessandro Santurro, Stefano D'Errico, Paola Frati, D'Errico, Stefano, Santurro, Alessandro, Scopetti, Matteo, Frati, Paola, and Fineschi, Vittorio
- Subjects
Food induced anaphylaxis ,Immunology ,Case Report ,Tryptase ,Immunoglobulin E ,Beta Tryptase ,03 medical and health sciences ,food allergens ,food-induced allergy ,0302 clinical medicine ,mast-cells ,Immunology and Allergy ,Medicine ,030216 legal & forensic medicine ,Food allergens ,Pathological ,beta tryptase ,IgE ,Wheat ,Pharmacology ,biology ,business.industry ,Fatal anaphylaxis ,030228 respiratory system ,biology.protein ,Cadaveric spasm ,business ,food allergen - Abstract
Post-mortem investigation in cases of fatal anaphylaxis is required to provide clarifications on the presence of macroscopic pathological changes, histological features, and immunohistochemical positivity suggestive of the diagnosis, on biochemical evidence of anaphylaxis and on the presence of serological data indicative of the allergen responsible for the anaphylactic reaction. We describe the case of a 16-year-old boy with a medical history of allergic asthma, celiac disease, and known food-induced allergy for fish, fresh milk, peanuts, hazelnuts, walnuts, apples, kiwis, and peaches. Acute onset of dyspnea followed by cyanosis of the lips and respiratory failure was described immediately after having an ice cream sandwich. Unsuccessful rescues were immediately attempted with oral administration of betamethasone, intramuscular injection of adrenaline, and cardiopulmonary resuscitation. A complete post-mortem examination was performed. Serum dosage of mast cell beta-tryptase from femoral blood detecting serum values of 41.4 mg/l. Determination of specific IgE on cadaveric blood samples confirmed the anamnestic data related to sensitization for several food allergens, including cod parvalbumin, tropomyosin, brazil nut, omega-5-gliadin of foods derived from wheat and gluten. The cause of death was identified in a cardiorespiratory failure due to anaphylactic shock in a poly-allergic subject and anaphylaxis was ascribed to the wheat contained in the ice cream sandwich eaten immediately before the onset of respiratory symptoms. The need is to implement an interdisciplinary approach capable to ascertain the sensitivity and specificity of the diagnostic tests currently in use as well as to evaluate the possibility of introducing new biomarkers in practice.
- Published
- 2020
36. Fatal Anaphylaxis Due to Graded Drug Challenge: A Cautionary Tale
- Author
-
Roland Solensky
- Subjects
Drug ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,MEDLINE ,Fatal anaphylaxis ,medicine.disease ,Amoxicillin-Potassium Clavulanate Combination ,Dermatology ,medicine ,Immunology and Allergy ,Humans ,business ,Anaphylaxis ,media_common - Published
- 2019
37. Peanut Allergy: New Advances and Ongoing Controversies
- Author
-
Elissa M. Abrams, Scott H. Sicherer, and Edmond S. Chan
- Subjects
medicine.medical_specialty ,Allergy ,Arachis ,medicine.medical_treatment ,Peanut allergy ,medicine ,Humans ,Epinephrine autoinjector ,Peanut Hypersensitivity ,Intensive care medicine ,Child ,Anaphylaxis ,Sensitization ,Desensitization (medicine) ,Minimal risk ,business.industry ,food and beverages ,Fatal anaphylaxis ,Diagnostic test ,medicine.disease ,Review Literature as Topic ,medicine.anatomical_structure ,Desensitization, Immunologic ,Pediatrics, Perinatology and Child Health ,Quality of Life ,Immunotherapy ,business - Abstract
Peanut allergy is one of the most common food allergies in children, with increasing prevalence over time. The dual-allergen exposure hypothesis now supports transcutaneous sensitization to peanut as a likely pathophysiologic mechanism for peanut allergy development. As a result, there is emerging evidence that early peanut introduction has a role in peanut allergy prevention. Current first-line diagnostic tests for peanut allergy have limited specificity, which may be enhanced with emerging tools such as component-resolved diagnostics. Although management of peanut allergy includes avoidance and carrying an epinephrine autoinjector, risk of fatal anaphylaxis is extremely low, and there is minimal risk related to cutaneous or inhalational exposure. Quality of life in children with peanut allergy requires significant focus. Moving forward, oral and epicutaneous immunotherapy are emerging and exciting tools that may have a role to play in desensitization to peanut.
- Published
- 2019
38. Fatal anaphylaxis: making sure all cases are counted
- Author
-
Adam T. Fox, Vibha Sharma, and Tomaz Garcez
- Subjects
medicine.medical_specialty ,Food induced anaphylaxis ,business.industry ,Fatal anaphylaxis ,Improved survival ,General Medicine ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Food anaphylaxis ,Emergency medicine ,Case fatality rate ,medicine ,030212 general & internal medicine ,business - Abstract
Baseggio Conrado and colleagues note that, although hospital admissions for food induced anaphylaxis increased between 1998 and 2018, the case fatality rate for confirmed food anaphylaxis decreased over this 20 year period, from 0.7% to 0.19%.1 Improved survival might result from better management, but misclassification of deaths should also be considered, especially as fatalities are rare. Having evaluated deaths for the United Kingdom Fatal Anaphylaxis Registry (UKFAR), we raise the …
- Published
- 2021
- Full Text
- View/download PDF
39. Clinical characteristics of fatal anaphylaxis: A Spanish nationwide 17- year series
- Author
-
Marianela Managua Brandoni Petrone, Jimena Laiseca Garcia, Sabela Perez Codesido, Lucia Gonzalez-Bravo, Patricia Alejandra Andraden Garban, Marta Goyanes Malumbres, and M.A. Tejedor
- Subjects
Pediatrics ,medicine.medical_specialty ,Series (stratigraphy) ,business.industry ,Immunology ,Immunology and Allergy ,Medicine ,Fatal anaphylaxis ,business - Published
- 2021
- Full Text
- View/download PDF
40. Incidence Of Fatal Anaphylaxis: A Systematic Review And Meta-analysis Of Observational Studies. Sources Of Information
- Author
-
M.A. Tejedor, Jimena Laiseca-Garcia, Marianela Brandoni-Petrone, Patricia Andrade-Garban, Sabela Perez Codesido, Lucia Gonzalez-Bravo, and Marta Goyanes-Malumbres
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Meta-analysis ,Incidence (epidemiology) ,Immunology ,medicine ,Immunology and Allergy ,Fatal anaphylaxis ,Observational study ,business - Published
- 2021
- Full Text
- View/download PDF
41. Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
- Author
-
Young Rim Song, Seung Hun Jang, Ji Young Park, Jwa-Kyung Kim, Joo-Hee Kim, Hyung Seok Lee, and Sung Gyun Kim
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,MEDLINE ,Fatal anaphylaxis ,Immunology and Allergy ,Medicine ,Hemodialysis ,business ,Intensive care medicine ,Letter to the Editor ,Nafamostat mesylate - Published
- 2021
- Full Text
- View/download PDF
42. Anaphylaxis in adolescents
- Author
-
Joseph D. Spahn, Pasquale Comberiati, and Diego Peroni
- Subjects
Adult ,Risk ,medicine.medical_specialty ,Adolescent ,Immunology ,Vulnerability ,Young Adult ,Age groups ,Environmental health ,Epidemiology ,medicine ,Animals ,Humans ,Immunology and Allergy ,Young adult ,Anaphylaxis ,business.industry ,Self-Management ,Incidence (epidemiology) ,Age Factors ,Fatal anaphylaxis ,medicine.disease ,Age distribution ,business ,Food Hypersensitivity - Abstract
Purpose of review The frequency of hospitalization for anaphylaxis has increased over the last 20 years across Europe, Australia, and North America, particularly, for food and medication triggers. Adolescents show the highest risk for morbidity and fatality from food-induced anaphylaxis, yet there is little high-quality evidence addressing the reasons for this disproportionate vulnerability. Recent findings Recent data seem to suggest a possible increasing burden of food-induced anaphylaxis among adolescents. Trends in anaphylaxis mortality are stable in North America and the United Kingdom, but not in Australia where the incidence of fatal anaphylaxis has recently doubled. The age distribution of fatal anaphylaxis varies according to the nature of the culprit trigger, with data suggesting an age-related predisposition to fatal food anaphylaxis in adolescents and young adults. Adolescence represents a critical phase of transition when rapid and substantial physical, emotional, and social changes occur. Therefore, adolescents show challenges in self-management that are different from other age groups, contributing to a higher risk of poor anaphylaxis outcomes. Summary The purpose of this review is to summarize recent data on epidemiology and elicitors of anaphylaxis in adolescents and to address currently known barriers and potential facilitators to self-management of anaphylaxis in this vulnerable age group.
- Published
- 2019
43. Is unrecognized anaphylaxis a cause of sudden unexpected death?
- Author
-
Schwartz, H. J., Yunginger, J. W., and Schwartz, L. B.
- Subjects
- *
DEATH , *ANAPHYLAXIS , *ALLERGIES , *IMMUNOGLOBULINS , *TOXINS , *VENOM - Abstract
Background Serum tryptase levels reflect mast cell activation and correlate with anaphylactic reactions. Elevated post-mortem serum tryptase levels have been found in witnessed fatal anaphylaxis. Objective This study was designed to examine whether or not unwitnessed anaphylaxis may be a hitherto unrecognized cause of sudden unexplained death. Methods Mast cell tryptase was measured by immunoassay in 68 post-mortem sera remaining from a previous study which reported elevated venom-specific IgE antibodies in 22 (23%) of 94 victims of sudden unexpected death. Autopsies were performed in all cases. The cause of death was independently reported by pathologists unfamiliar with the nature of this study. Results Serum tryptase levels were elevated (> 10 ng/mL) in nine of 68 cases. The levels could not be predicted from the clinical circumstances surrounding death. Sera from four individuals contained both elevated tryptase and previously reported elevated venom-specific IgE. Conclusions We conclude that mast cell activation may accompany up to 13% of sudden unexpected deaths in adults. Measurement of both tryptase and specific IgE antibody levels in post-mortem sera from persons experiencing sudden, unexpected death may identify a small subset of cases due to clinically unrecognized fatal anaphylaxis, including those due to insect stings. [ABSTRACT FROM AUTHOR]
- Published
- 1995
- Full Text
- View/download PDF
44. Fatal Anaphylaxis to Atracurium: A Case Report
- Author
-
Jan Schumacher
- Subjects
Male ,Resuscitation ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Fatal anaphylaxis ,General Medicine ,Cystoscopy ,Middle Aged ,medicine.disease ,Fentanyl ,Fatal Outcome ,Anesthesia ,medicine ,Atracurium ,Humans ,Cardiopulmonary resuscitation ,Propofol ,business ,Intraoperative Complications ,Anaphylaxis ,medicine.drug ,Neuromuscular Nondepolarizing Agents - Abstract
A 52-year-old patient was scheduled for a cystoscopy. Anesthesia was induced by intravenous injection of fentanyl and propofol. After administration of atracurium, he became bradycardic and suffered a cardiac arrest. Despite prolonged cardiopulmonary resuscitation, the patient could not be revived. Electrolytes and hemoglobin levels were normal, and a transthoracic echocardiogram showed no signs of pericardial effusions or of any left ventricular contraction. The postmortem found no pathology. However, mast cell tryptase was raised significantly, indicating fatal anaphylaxis. Having presented no classic clinical signs, this case is a reminder that rapid cardiovascular collapse can be the sole clinical feature of anaphylaxis.
- Published
- 2018
45. [ANALYSIS OF DRUG-INDUCED ANAPHYLAXIS CASES USING THE JAPANESE ADVERSE DRUG EVENT REPORT DATABASE].
- Author
-
Sugizaki C, Sato S, Yanagida N, and Ebisawa M
- Subjects
- Adverse Drug Reaction Reporting Systems, Biological Factors adverse effects, Humans, Japan epidemiology, Anaphylaxis chemically induced, Anaphylaxis epidemiology, Drug-Related Side Effects and Adverse Reactions epidemiology
- Abstract
Background: The epidemiology of drug-induced anaphylaxis (AN) using the Japanese nationwide database has not been reported, even though drugs are a common trigger of AN., Objective: This study aimed to describe the epidemiological profile of drug-induced AN, including fatal cases, using the Japanese Adverse Drug Event Report database (JADER)., Methods: We extracted data regarding drug-induced adverse events between April 2004 and February 2018 published in JADER by the Pharmaceuticals and Medical Devices Agency. We analyzed cases of anaphylaxis occurring between January 2005 and December 2017. The drug classification was based on the Japanese Standard Commodity Classification., Results: There were 16916 cases of anaphylaxis reported during the study period. Among them, 418 fatalities were registered. The incidence of drug-induced AN and fatal cases was 1.03 cases/year per 100000 population and 0.03 cases/year, respectively. The most frequent causes of AN were diagnostic agents including X-ray contrast media (20.3%) and biological agents including human blood preparations (20.1%). In fatal cases, diagnostic agents (28.7%) and antibiotics (23.9%) were the most frequent causes., Conclusions: The frequency of drug-induced AN and fatalities in Japan remained unchanged over the 12-year period analyzed in this study. Diagnostic and biological agents were the most frequent causes of AN. Contrarily, fatalities were most frequently caused by diagnostic and antibiotic agents.
- Published
- 2022
- Full Text
- View/download PDF
46. Applying the Behavioural Intervention Technologies model to the development of a smartphone application (app) supporting young peoples’ adherence to anaphylaxis action plan
- Author
-
Joanna K. Anderson and Louise M. Wallace
- Subjects
Fatal outcome ,Evidence-based practice ,Smart phone ,business.industry ,Behavioural intervention ,Fatal anaphylaxis ,Anaphylaxis action plan ,General Medicine ,Smartphone application ,Computer security ,computer.software_genre ,medicine.disease ,Hospital admission ,Medicine ,Medical emergency ,business ,computer - Abstract
The incidence of fatal anaphylaxis is significantly higher among young people aged 15–25 compared with other age groups. Hospital admission or fatal outcome following anaphylaxis often results from failure to adhere to an agreed anaphylaxis action plan (AAP). The main barriers for adherence include lack of confidence to recognise symptoms of severe reaction, lack of confidence and skills to correctly use an adrenaline auto-injector (AAI), and not having the AAI available when needed. We describe the development of a smart phone application (app) to increase young peoples’ adherence to AAP. The development of the app was informed by information from a literature review to identify factors enhancing and impeding young peoples’ adherence to their AAP, combined with data from consultations with intended users and clinicians working with young people at risk of anaphylaxis regarding their needs and expectations with regard to the content and technical features of the app. The design process was underpinned by the novel Behavioural Intervention Technologies model. This ensured that the apps’ content is evidence based, complies with current guidelines, and responds to users’ needs and preferences in relation to content and technical characteristics. ‘Anaphylaxis’ app is the first smart phone app that comprises a comprehensive personalised AAP. Since its launch in February 2013, it has been downloaded by approximately 16 000 users worldwide. Further research is required to demonstrate its effectiveness in improving self-management of anaphylactic risk in young people.
- Published
- 2015
- Full Text
- View/download PDF
47. Fatal anaphylaxis from hymenoptera stings
- Author
-
Alok Atreya, Raghvendra Singh Shekhawat, and Tanuj Kanchan
- Subjects
medicine.medical_specialty ,Hymenoptera ,Insect bites and stings ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,Humans ,030212 general & internal medicine ,Anaphylaxis ,Aged ,biology ,business.industry ,Insect Bites and Stings ,Fatal anaphylaxis ,General Medicine ,Forensic Medicine ,medicine.disease ,biology.organism_classification ,Dermatology ,eye diseases ,Insect stings ,Sting ,030228 respiratory system ,Female ,business - Abstract
Venomous insect stings are a cause of morbidity and mortality worldwide. The sting reactions are unpredictable and vary among individuals. A case of fatal insect sting in an elderly female is presented to discuss the associated challenges during necropsy.
- Published
- 2016
- Full Text
- View/download PDF
48. Contribution of my faculty in Food Protein Allergy
- Author
-
Nikita Raosaheb More and Nilakshi S. Pradhan
- Subjects
Allergy ,medicine.medical_specialty ,Food protein ,business.industry ,Fatal anaphylaxis ,medicine.disease ,Dermatology ,medicine.anatomical_structure ,Food allergy ,medicine ,Vomiting ,Hay fever ,medicine.symptom ,business ,Nose ,Natural immune system - Abstract
An allergy is a hypersensitive reaction of the body when it comes into contact with a substance that is in fact harmless .An allergy is certain cause occurs suddenly and is predictable . The hypersensitive response comes from the natural immune system and ranges from a slightly uncomfortable feeling to a fatal anaphylaxis. Light allergies are part everyday life . Allergic rhinitis , hay fever characterized by runny nose ,red eyes and itchiness. Food allergy causes vomiting, watery stools, rashes, substances that causes allergy often are proteins in food such as milk, wheat, beef, eggs, and so on the allergy, such as blood tests, skin tests etc. Ocular allergy includes several clinically different conditions that can be considered as hypersensitivity disorders of ocular surface. Ocular allergy symptoms are often but not always associated with other allergic manifestation mostly rhinitisSometimes the eyes can react to other allergens that don’t necessarily come in direct contact with the eye, such as specific type of food material.
- Published
- 2018
- Full Text
- View/download PDF
49. Food-induced fatal anaphylaxis: From epidemiological data to general prevention strategies
- Author
-
J.-M. Renaudin, Margitta Worm, Antoine Deschildre, Pascal Demoly, Guillaume Pouessel, Luciana Kase Tanno, Victoria Cardona, Paul Turner, Etienne Beaudouin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service d'allergologie et de pneumologie [Hôpital Arnaud de Villeneuve], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Sorbonne Université (SU)
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Allergy ,[SDV]Life Sciences [q-bio] ,Immunology ,MEDLINE ,CINAHL ,mortality rate ,03 medical and health sciences ,0302 clinical medicine ,fatality ,Risk Factors ,Food allergy ,Epidemiology ,medicine ,anaphylaxis ,Humans ,Immunology and Allergy ,Public Health Surveillance ,Intensive care medicine ,Cause of death ,business.industry ,Mortality rate ,fatal anaphylaxis ,Age Factors ,Allergens ,medicine.disease ,mortality ,3. Good health ,030104 developmental biology ,1117 Public Health And Health Services ,030228 respiratory system ,Food ,1107 Immunology ,food-induced anaphylaxis ,business ,Food Hypersensitivity ,Anaphylaxis - Abstract
BACKGROUND: Anaphylaxis hospitalisations are increasing in many countries, in particular for medication and food triggers in young children. Food-related anaphylaxis remains an uncommon cause of death, but a significant proportion of these are preventable. AIM: To review published epidemiological data relating to food-induced anaphylaxis and potential risk factors of fatal and/or near-fatal anaphylaxis cases, in order to provide strategies to reduce the risk of severe adverse outcomes in food anaphylaxis. METHODS: We identified 32 published studies available in MEDLINE (1966-2017), EMBASE (1980-2017), CINAHL (1982-2017), using known terms and synonyms suggested by librarians and allergy specialists. RESULTS: Young adults with a history of asthma, previously known food allergy particularly to peanut/tree nuts are at higher risk of fatal anaphylaxis reactions. In some countries, cow's milk and seafood/fish are also becoming common triggers of fatal reactions. Delayed adrenaline injection is associated with fatal outcomes, but timely adrenaline alone may be insufficient. There is still a lack of evidence regarding the real impact of these risk factors and co-factors (medications and/or alcohol consumption, physical activities, and mast cell disorders). CONCLUSIONS: General strategies should include optimization of the classification and coding for anaphylaxis (new ICD 11 anaphylaxis codes), dissemination of international recommendations on the treatment of anaphylaxis, improvement of the prevention in food and catering areas and, dissemination of specific policies for allergic children in schools. Implementation of these strategies will involve national and international support for ongoing local efforts in relationship with networks of centres of excellence to provide personalized management (which might include immunotherapy) for the most at-risk patients. This article is protected by copyright. All rights reserved.
- Published
- 2018
- Full Text
- View/download PDF
50. Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules
- Author
-
Pascal Demoly, Ségolène Aymé, Luciana Kase Tanno, Isabella Annesi-Maesano, F. Estelle R. Simons, Moises A. Calderon, Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Emergency Department [São Paulo, Brazil], Hospital Sírio-Libanês [São Paulo, Brazil], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Department of Pediatrics & Child Health [Winnipeg, Canada], Section of Allergy & Clinical Immunology [Winnipeg, Canada], University of Manitoba [Winnipeg]-University of Manitoba [Winnipeg], Section of Allergy and Clinical Immunology [London, UK], Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, Plateforme d'information et de services pour les maladies rares et les médicaments orphelins (Orphanet), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Broussais-Institut National de la Santé et de la Recherche Médicale (INSERM), and BMC, BMC
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Underlying cause of death ,[SDV]Life Sciences [q-bio] ,Pharmacology toxicology ,Review ,World Health Organization ,World health ,03 medical and health sciences ,0302 clinical medicine ,International Classification of Diseases ,Humans ,Medicine ,Genetics(clinical) ,Pharmacology (medical) ,Registries ,Mortality ,Intensive care medicine ,Anaphylaxis ,Genetics (clinical) ,Medicine(all) ,business.industry ,Clinical Coding ,Fatal anaphylaxis ,General Medicine ,medicine.disease ,Classification ,3. Good health ,[SDV] Life Sciences [q-bio] ,Hypersensitivity reaction ,030104 developmental biology ,030228 respiratory system ,Icd codes ,business ,Coding (social sciences) - Abstract
International audience; AbstractAnaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction. The difficulty of coding anaphylaxis fatalities under the World Health Organization (WHO) International Classification of Diseases (ICD) system is recognized as an important reason for under-notification of anaphylaxis deaths. On current death certificates, a limited number of ICD codes are valid as underlying causes of death, and death certificates do not include the word anaphylaxis per se. In this review, we provide evidences supporting the need for changes in WHO mortality coding rules and call for addition of anaphylaxis as an underlying cause of death on international death certificates. This publication will be included in support of a formal request to the WHO as a formal request for this move taking the 11th ICD revision.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.